Central Ayurveda Research Institute Microcrystalline Cellulose 102 Pharmacopoeial Grade Tender Jhansi Uttar Pradesh 2026

Tender Overview

• Organization: Central Ayurveda Research Institute, under the Central Council For Research In Ayurvedic Sciences.
• Product: Microcrystalline Cellulose 102 Pharmacopoeial Grade (category focused on pharmacopeial excipient quality).
• Location: Jhansi, Uttar Pradesh 284001.
• Scope & Value: Procurement opportunity with unspecified quantity and value; relies on option clauses for quantity adjustments up to 25% during and after contract formation.
• Delivery & Expansion: Delivery window adjusts with option, calculated as (increased quantity ÷ original quantity) × original delivery period, with a minimum of 30 days; extension possible up to the original delivery period.
• Unique aspect: The contract terms explicitly reserve quantity expansion rights and time extensions, which bidders must accommodate in planning and pricing.
• Context: Tender is issued by a government research body focusing on Ayurvedic sciences and related excipients, reflecting strict pharmacopeial compliance expectations.
• Keywords: tender in Jhansi, Central Ayurveda Research Institute procurement, Microcrystalline Cellulose bid 2026.

Technical Specifications & Requirements

• Product name: Microcrystalline Cellulose 102 Pharmacopoeial Grade (no additional BOQ lines available).
• Quality framework: No explicit specifications published; bidders should assume pharmacopeial grade compliance and related quality controls typical for excipients.
• Delivery terms: Standard delivery terms tied to option clause; delivery period begins after the last delivery order date.
• Compliance expectations: In the absence of explicit standards in the data, bidders should prepare documentation demonstrating pharmacopeial grade production and supply readiness, with traceability and quality assurance records.
• Documentation readiness: OEM or manufacturer identity and regulatory alignment may be implied; ensure standard GMP-like documentation is prepared.
• Experience signals: Although not stated, bidders with excipient supply to government or pharmaceutical entities will be advantaged.

Terms, Conditions & Eligibility

• EMD: Not specified in the available data.
• Quantity flexibility: Up to 25% increase in quantity at contracted rates during and after contract; expansion time computed with a minimum of 30 days.
• Delivery timeline: Extended delivery time is calculated as above; must be feasible within overall contract window.
• Payment terms: Not disclosed in the provided information; bidders should prepare standard government procurement payment documentation.
• ATC/AT terms: Buyer Added ATC indicates formal ATC document exists; bidders should review attached ATC for any additional obligations.
• BOQ: No items listed in BOQ; implies a potentially single-line or non-quantified procurement exercise at this stage.
• Submission readiness: Ensure pharmacopeial grade certifications and supplier credentials are up-to-date to align with potential government requirements.